Literature DB >> 25142588

APOBEC3F determinants of HIV-1 Vif sensitivity.

Allison M Land1, Nadine M Shaban1, Leah Evans1, Judd F Hultquist1, John S Albin1, Reuben S Harris2.   

Abstract

HIV-1 Vif counteracts restrictive APOBEC3 proteins by targeting them for proteasomal degradation. To determine the regions mediating sensitivity to Vif, we compared human APOBEC3F, which is HIV-1 Vif sensitive, with rhesus APOBEC3F, which is HIV-1 Vif resistant. Rhesus-human APOBEC3F chimeras and amino acid substitution mutants were tested for sensitivity to HIV-1 Vif. This approach identified the α3 and α4 helices of human APOBEC3F as important determinants of the interaction with HIV-1 Vif.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25142588      PMCID： PMC4248952          DOI： 10.1128/JVI.02362-14

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  20 in total

1.  Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.

Authors:  Qin Yu; Renate König; Satish Pillai; Kristopher Chiles; Mary Kearney; Sarah Palmer; Douglas Richman; John M Coffin; Nathaniel R Landau
Journal:  Nat Struct Mol Biol       Date:  2004-04-18       Impact factor: 15.369

2.  Antiretroviral activity and Vif sensitivity of rhesus macaque APOBEC3 proteins.

Authors:  Cesar A Virgen; Theodora Hatziioannou
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

Review 3.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

4.  Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.

Authors:  John S Albin; Guylaine Haché; Judd F Hultquist; William L Brown; Reuben S Harris
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells.

Authors:  M Janini; M Rogers; D R Birx; F E McCutchan
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

6.  Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction.

Authors:  Eric W Refsland; Mark D Stenglein; Keisuke Shindo; John S Albin; William L Brown; Reuben S Harris
Journal:  Nucleic Acids Res       Date:  2010-03-22       Impact factor: 16.971

7.  A new type of G-->A hypermutation affecting human immunodeficiency virus.

Authors:  J E Fitzgibbon; S Mazar; D T Dubin
Journal:  AIDS Res Hum Retroviruses       Date:  1993-09       Impact factor: 2.205

8.  Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G.

Authors:  Guylaine Haché; Keisuke Shindo; John S Albin; Reuben S Harris
Journal:  Curr Biol       Date:  2008-05-22       Impact factor: 10.834

9.  Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates.

Authors:  Véronique Zennou; Paul D Bieniasz
Journal:  Virology       Date:  2006-02-07       Impact factor: 3.616

10.  Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya.

Authors:  Allison M Land; T Blake Ball; Ma Luo; Richard Pilon; Paul Sandstrom; Joanne E Embree; Charles Wachihi; Joshua Kimani; Francis A Plummer
Journal:  J Virol       Date:  2008-06-11       Impact factor: 5.103
View more
  10 in total

1.  Structural Insights into HIV-1 Vif-APOBEC3F Interaction.

Authors:  Masaaki Nakashima; Hirotaka Ode; Takashi Kawamura; Shingo Kitamura; Yuriko Naganawa; Hiroaki Awazu; Shinya Tsuzuki; Kazuhiro Matsuoka; Michiko Nemoto; Atsuko Hachiya; Wataru Sugiura; Yoshiyuki Yokomaku; Nobuhisa Watanabe; Yasumasa Iwatani
Journal:  J Virol       Date:  2015-11-04       Impact factor: 5.103

2.  Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.

Authors:  Zeli Zhang; Qinyong Gu; Ananda Ayyappan Jaguva Vasudevan; Manimehalai Jeyaraj; Stanislaw Schmidt; Jörg Zielonka; Mario Perković; Jens-Ove Heckel; Klaus Cichutek; Dieter Häussinger; Sander H J Smits; Carsten Münk
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

3.  The Binding Interface between Human APOBEC3F and HIV-1 Vif Elucidated by Genetic and Computational Approaches.

Authors:  Christopher Richards; John S Albin; Özlem Demir; Nadine M Shaban; Elizabeth M Luengas; Allison M Land; Brett D Anderson; John R Holten; John S Anderson; Daniel A Harki; Rommie E Amaro; Reuben S Harris
Journal:  Cell Rep       Date:  2015-11-25       Impact factor: 9.423

Review 4.  Structural perspectives on HIV-1 Vif and APOBEC3 restriction factor interactions.

Authors:  Farshad C Azimi; Jeffrey E Lee
Journal:  Protein Sci       Date:  2019-11-29       Impact factor: 6.725

5.  A computational analysis of the structural determinants of APOBEC3's catalytic activity and vulnerability to HIV-1 Vif.

Authors:  Shivender M D Shandilya; Markus-Frederik Bohn; Celia A Schiffer
Journal:  Virology       Date:  2014-10-29       Impact factor: 3.616

6.  1.92 Angstrom Zinc-Free APOBEC3F Catalytic Domain Crystal Structure.

Authors:  Nadine M Shaban; Ke Shi; Ming Li; Hideki Aihara; Reuben S Harris
Journal:  J Mol Biol       Date:  2016-04-30       Impact factor: 5.469

7.  Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.

Authors:  Jiayi Wang; Nadine M Shaban; Allison M Land; William L Brown; Reuben S Harris
Journal:  J Virol       Date:  2018-05-29       Impact factor: 5.103

8.  APOBEC3F Constitutes a Barrier to Successful Cross-Species Transmission of Simian Immunodeficiency Virus SIVsmm to Humans.

Authors:  Rayhane Nchioua; Dorota Kmiec; Amit Gaba; Christina M Stürzel; Tyson Follack; Stephen Patrick; Andrea Kirmaier; Welkin E Johnson; Beatrice H Hahn; Linda Chelico; Frank Kirchhoff
Journal:  J Virol       Date:  2021-08-10       Impact factor: 5.103

9.  Degradation of the cancer genomic DNA deaminase APOBEC3B by SIV Vif.

Authors:  Allison M Land; Jiayi Wang; Emily K Law; Ryan Aberle; Andrea Kirmaier; Annabel Krupp; Welkin E Johnson; Reuben S Harris
Journal:  Oncotarget       Date:  2015-11-24

10.  Determinants of FIV and HIV Vif sensitivity of feline APOBEC3 restriction factors.

Authors:  Zeli Zhang; Qinyong Gu; Ananda Ayyappan Jaguva Vasudevan; Anika Hain; Björn-Philipp Kloke; Sascha Hasheminasab; Daniel Mulnaes; Kei Sato; Klaus Cichutek; Dieter Häussinger; Ignacio G Bravo; Sander H J Smits; Holger Gohlke; Carsten Münk
Journal:  Retrovirology       Date:  2016-07-01       Impact factor: 4.602
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.